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Renal dysfunction has become a validated
prognostic factor indicating increased
morbidity and mortality in different
cardiovascular diseases, such as acute
coronary syndrome1 or chronic heart
failure.2 Impaired kidney function may
not only reflect chronic renal disease but
also deterioration secondary to haemody-
namic disturbances, as decreased cardiac
output and elevated central venous pres-
sure may contribute to renal insuffi-
ciency.3 Kidney dysfunction has
previously been observed in patients with
acute pulmonary embolism (APE) and was
found to be associated with worse short-
term outcomes.4 5 However, those studies
were not able to distinguish between
acute kidney injury due to haemodynamic
compromise cause by APE or chronic pre-
existing renal insufficiency.
Kostrubiec and co-workers6 investigated
markers of acute kidney injury such as
cystatin C and serum neutrophil gelati-
nase-associated lipocalin (N-GAL) and
their association with left and right heart
function, disease severity, and prognosis in
patients with APE. Cystatin C is a 13 kDa
endogenous cysteine proteinase inhibitor
and is produced by nucleated cells at
a constant rate. It is freely filtered by the
glomerulus, reabsorbed and catabolised,
but it is not secreted by the tubules.
Earlier studies demonstrated the superi-
ority of serum cystatin C compared with
creatinine, especially to detect minor
changes in glomerular filtration rate
(GFR).7 In addition, it was suggested that
serum cystatin C performed better than
creatinine as a marker to detect acute GFR
reductions.8 The release of N-GAL repre-
sents an intrinsic response of the proximal
renal tubule cells to ischaemic injury of
the kidney. In the animal model, the
response is extremely rapid, with N-GAL
appearing in the first urine portion after
the acute kidney injury.9 Serum N-GAL
elevation was found to indicate acute GFR
reductions much faster than creatinine
measurements in different clinical condi-
tions, for example, in patients undergoing
cardiac surgery10 or percutaneous coro-
nary interventions.11 The determination
of cystatin C and serum N-GAL might
thus be appropriate tools for detecting
acute kidney injury secondary to haemo-
dynamic compromise or hypoxaemia
resulting from APE.
The authors investigated 142 consecu-
tive patients with APE. The all-cause
mortality rate up to 30 days after the
diagnosis of APE was 10%, nine deaths
(6%) were found to be pulmonary embo-
lism related. The estimated glomerular
filtration rate (eGFR) was noted to be
60 ml/min per 1.73 m2 or less in 48% of
the study population. Both, N-GAL and
cystatin C levels significantly correlated
with the eGFR. In contrast to cystatin C,
serum N-GAL concentrations were signif-
icantly higher in patients who died from
APE. Decrease in eGFR as well as eleva-
tions of cystatin C and serum N-GAL
were significant predictors of all-cause and
pulmonary embolism-related 30-day
mortality in univariate analysis. However,
only cystatin C levels independently
predicted 30-day all-cause mortality but
not PE-related deaths in the multivariate
analysis. Both cystatin C and N-GAL
elevations were associated with less
favourable clinical outcomes in the
KaplaneMeier analysis. Left ventricular
ejection fractions correlated with both
eGFR and cystatin C levels, while plasma
N-GAL concentrations were found to
correlate with right ventricular function
parameters assessed by echocardiography.
Other risk stratification models such as
the simplified pulmonary embolism
severity index significantly correlated with
eGFR, cystatin C levels and serum N-GAL
concentrations.
In contrast to previous studies4 5 the
authors were able to demonstrate that
haemodynamic compromise during APE
might have contributed to renal dysfunc-
tion, as markers of acute kidney injury
were associated with signs of acute right
ventricular dysfunction or increased
central venous pressure. Sudden pressure
overload in the pulmonary circulation due
to APE may lead to acute right ventricular
dysfunction along with tricuspid regurgi-
tation. As a consequence, central venous
pressure rises and may lead to renal
dysfunction by a stagnation of venous
blood flow in the kidneys.12 The findings
of the study are new and possibly repre-
sent an important step forward in the
understanding of the interactions between
the cardiopulmonary and renal systems
during APE. On the other hand, the study
included many patients with relevant
comorbidities, such as diabetes mellitus
and congestive heart failure, which are
well known to affect kidney function
themselves. As a consequence, the eGFR
was found to be reduced in nearly one out
of two study participants. Therefore, both
cystatin C and N-GAL elevations might
have been aggravated by chronic pre-
existing renal insufficiency.
The results of the present study under-
line the notion that renal dysfunction
may be associated with a worse prognosis
of patients with APE and, therefore, might
represent an additional aspect in risk
stratification. A number of clinical and
instrumental findings such as haemody-
namic instability, right ventricular
dysfunction or myocardial injury have
been associated with a high risk of adverse
short-term clinical outcomes in patients
with APE and are the basis of risk strati-
fication according to current guidelines.13
Therefore, particularly in haemodynami-
cally stable patients who are believed to be
at low risk of death, markers of acute
kidney injury might be additionally
helpful in risk stratification, as signs of
right ventricular dysfunction or myocar-
dial injury are missing and both cystatin C
and N-GAL elevations showed very high
negative predictive values in the estima-
tion of the all-cause mortality in this
subgroup of patients. However, the results
of this single-centre trial have to be inter-
preted with caution, as the statistical
analysis is limited by the relatively small
numbers of study participants and the
low death rates. For example, the evalua-
tion for pulmonary embolism-related 30-
day mortality is based on the outcome
analysis of only nine patients. The small
study size might explain the partially
inconsistent findings of the study, as the
results might have been biased by
concomitant factors such as age or
comorbidity even after forward stepwise
multivariate analysis.
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Is the evaluation of renal function a new
aspect in the risk stratification of patients
with APE? The study of Kostrubiec and
colleagues6 is promising, but it is too early
to answer the question. Larger multicentre
studies need to follow, and markers of
acute kidney injury have to be validated
against other biomarkers such as brain-type
natriuretic peptide or troponin, which are
already accepted components in risk strat-
ifications models of patients with APE.14
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